Kearny Venture Partners
VC Fund
San Francisco, United States
Kearny Venture Partners is a VC fund in San Francisco focused on Health Care and Biotechnology. With over $330 million in capital under management, Kearny Venture Partners is a venture capital firm exclusively focused on healthcare products. We believe that the opportunity for entrepreneurs to devise innovative solutions in healthcare has never been greater. Significant unmet needs in healthcare continue to persist, representing largepotential market opportunities for safe and effective products. As the molecular basis of disease is increasingly unraveled, new opportunities for intervention emerge. Novel therapies can and will displace incumbent products.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 7%
Last updated:
For AI agents: llms.txt
Industries Kearny Venture Partners invests in
Health CareBiotechnologyTherapeuticsMedical DeviceManufacturing
Stages Kearny Venture Partners invests in
Series BSeries CSeries ASeries DSeries E
Countries Kearny Venture Partners invests in
United StatesCanada
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew Jensen
|
|||
Anupam Dalal
|
|||
Caley Castelein
|
|||
Dick Spalding
|
|||
Jim Shapiro
|
Investment Focus
Industry
- Health Care 6 (43%)
- Biotechnology 6 (43%)
- Therapeutics 3 (21%)
- Medical Device 3 (21%)
- Manufacturing 1 (7%)
Stage
- Series B 4 (29%)
- Series C 4 (29%)
- Series A 2 (14%)
- Series D 1 (7%)
- Series E 1 (7%)
Country
- United States 6 (43%)
- Canada 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Andrew Jensen
CFO
|
CFO | Total investments: 0 | Find email | |
|
Anupam Dalal
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Caley Castelein
Partner
|
Partner | Total investments: 0 | Find email | |
|
Dick Spalding
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Jim Shapiro
Managing Director
|
Managing Director | Total investments: 7 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Elektrofi
|
Elektrofi is a preclinical-stage company dedicated to redefining the standard of drug delivery by transforming the patient experience. Elektrofi’s formulation system can effectively process a wide range of therapeutic molecules. Their technology has the capacity to process large, increasingly complex and delicate proteins including monoclonalantibodies, bispecifics and fusion proteins.Founded in 2016, Elektrofi is based in Boston, Massachusetts, United States. | $112.3M / Series C / Aug 22, 2024 | |
Cybin
|
Cybin is a biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin's mission is to revolutionize mental healthcare. | $33.1M / Series B / Jul 01, 2020 | |
Aerpio Pharmaceuticals
|
Aerpio Pharmaceuticals is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds.It is managed by the same successful team from Akebia, employing a similar outsourced approach to pharmaceutical development.Aerpio Pharmaceuticals was founded in 2011 and is based in Cincinnati, Ohio, United States. | $40M / Mar 16, 2017 | |
TriVascular
|
TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma WineCountry. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature. | $40M / Series E / Nov 18, 2013 | |
|
TriVascular
|
TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma WineCountry. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature. | $60M / Series D / Jun 04, 2012 | |
ViewRay
|
ViewRay develops advanced radiation therapy technology for the treatment of cancer. It designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRItechnology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side effects from off-target radiation delivery.The company was incorporated in 2004 and is based in Cleveland, Ohio. | $10M / Debt Financing / Sep 02, 2011 | |
|
ViewRay
|
ViewRay develops advanced radiation therapy technology for the treatment of cancer. It designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRItechnology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side effects from off-target radiation delivery.The company was incorporated in 2004 and is based in Cleveland, Ohio. | $20M / Series C / Aug 25, 2010 | |
|
TriVascular
|
TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma WineCountry. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature. | $60M / Series C / Aug 12, 2010 | |
Baxano
|
Baxano, Inc. develops minimally invasive tools to restore spine function and preserve healthy tissue. The company offers iO-Flex System, which targets and decompresses bone and soft tissue in the foramen, lateral recess, and central canal for patients with single and multi-level mild, moderate, and severe stenosis. Its products comprise Neuro Checkdevice that allows the surgeon to confirm that the device is against the bone and the nerve is safely out of the way; MicroBlade ShaverTM instrument, which is used to remove the impinging bone and ligament; Guidewire; probes; and distal handles. The company was founded in 2005 and is based in San Jose, California. | $30M / Series C / Jun 23, 2010 | |
|
TriVascular
|
TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma WineCountry. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature. | $30M / Series B / Nov 16, 2009 | |
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Climate Investors
40,325 investors
Manufacturing Investors
24,696 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Climate VC Funds
33,091 investors
Manufacturing VC Funds
21,540 investors
FAQ
What does Kearny Venture Partners invest in?
Kearny Venture Partners invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series B and Series C stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kearny Venture Partners?
Public channels for Kearny Venture Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Kearny Venture Partners?
The team at Kearny Venture Partners includes Andrew Jensen (CFO), Anupam Dalal (Managing Director) and Caley Castelein (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
